Compare GHC & NAMS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | GHC | NAMS |
|---|---|---|
| Founded | 1877 | 2019 |
| Country | United States | Netherlands |
| Employees | N/A | 100 |
| Industry | Other Consumer Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.8B | 4.1B |
| IPO Year | 1994 | N/A |
| Metric | GHC | NAMS |
|---|---|---|
| Price | $1,163.55 | $32.68 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 8 |
| Target Price | N/A | ★ $46.75 |
| AVG Volume (30 Days) | 15.2K | ★ 1.1M |
| Earning Date | 05-12-2026 | 05-06-2026 |
| Dividend Yield | ★ 0.65% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 66.47 | N/A |
| Revenue | ★ $2,932,099,000.00 | N/A |
| Revenue This Year | $7.73 | $17.96 |
| Revenue Next Year | $4.37 | $540.65 |
| P/E Ratio | $17.28 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $882.21 | $17.97 |
| 52 Week High | $1,224.76 | $42.21 |
| Indicator | GHC | NAMS |
|---|---|---|
| Relative Strength Index (RSI) | 59.83 | 54.05 |
| Support Level | $1,028.08 | $30.34 |
| Resistance Level | $1,197.21 | $37.27 |
| Average True Range (ATR) | 32.50 | 1.63 |
| MACD | 2.12 | 0.15 |
| Stochastic Oscillator | 70.39 | 84.05 |
Graham Holdings Company is a diversified holding company with operations spanning educational services, television broadcasting, healthcare, manufacturing, automotive dealerships, and other businesses. The Company's education activities are conducted through Kaplan, whose services include academic preparation programs for international students, English-language programs, exam preparation, and career and academic advisement. These services are provided to students, schools, and colleges, both domestically and outside the United States. It operates through seven reportable segments: Kaplan International, Kaplan Higher Education, Kaplan Supplemental Education, Television Broadcasting, CSI, Manufacturing and Automotive, with key revenue coming from the Education and Automotive segments.
NewAmsterdam Pharma Co NV is a late-stage biopharmaceutical company with a mission to improve patient care in populations with metabolic diseases where currently approved therapies have not been adequate or well tolerated. Its product, obicetrapib, is a next-generation, oral, low-dose CETP inhibitor that is developed to potentially overcome the limitations of current LDL-C lowering treatments. The Company has one reportable segment, which comprises the discovery, development, and commercialization of transformative therapies for cardio-metabolic diseases.